What changed from existing technology?
This study shows that a protein called KDM4B helps kidney cancer cells avoid the immune system and become resistant to a type of cancer treatment called anti-PD-1 therapy.
This study identifies KDM4B as a new target for overcoming resistance to immune checkpoint inhibitors in kidney cancer, highlighting its role in both tumor progression and immune evasion through non-histone demethylation.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests that targeting KDM4B could be a potential strategy to enhance the effectiveness of anti-PD-1 therapy in kidney cancer patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.